211 related articles for article (PubMed ID: 25520081)
1. Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients.
Li X; Zhong X; Chen ZH; Xing YF; Wu DH; Chen J; Ma XK; Lin Q; Wen JY; Wei L; Wang TT; Ruan DY; Lin ZX; Wu XY; Dong M
Asian Pac J Cancer Prev; 2014; 15(22):9635-41. PubMed ID: 25520081
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
Li X; Zhong X; Chen ZH; Wang TT; Ma XK; Xing YF; Wu DH; Dong M; Chen J; Ruan DY; Lin ZX; Wen JY; Wei L; Wu XY; Lin Q
Asian Pac J Cancer Prev; 2015; 16(18):8665-70. PubMed ID: 26745134
[TBL] [Abstract][Full Text] [Related]
3. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
4. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
5. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels.
Huang G; Lai EC; Lau WY; Zhou WP; Shen F; Pan ZY; Fu SY; Wu MC
Ann Surg; 2013 Mar; 257(3):490-505. PubMed ID: 22868358
[TBL] [Abstract][Full Text] [Related]
6. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
7. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load.
Huang G; Yang Y; Shen F; Pan ZY; Fu SY; Lau WY; Zhou WP; Wu MC
Ann Surg Oncol; 2013 May; 20(5):1482-90. PubMed ID: 23247982
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
Kuzuya T; Katano Y; Kumada T; Toyoda H; Nakano I; Hirooka Y; Itoh A; Ishigami M; Hayashi K; Honda T; Goto H
J Gastroenterol Hepatol; 2007 Nov; 22(11):1929-35. PubMed ID: 17914972
[TBL] [Abstract][Full Text] [Related]
9. Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma.
Kim JH; Sinn DH; Kim K; Kim H; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Nov; 10(6):939-947. PubMed ID: 27282264
[TBL] [Abstract][Full Text] [Related]
10. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
[TBL] [Abstract][Full Text] [Related]
11. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues.
Toyoda H; Kumada T; Tada T; Sone Y; Fujimori M
J Vasc Interv Radiol; 2012 Mar; 23(3):317-22.e1. PubMed ID: 22265248
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
Lim SG; Mohammed R; Yuen MF; Kao JH
J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
[TBL] [Abstract][Full Text] [Related]
14. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
16. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
17. Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative.
Wang K; Jiang G; Jia Z; Zhu X; Ni C
Medicine (Baltimore); 2018 Jun; 97(22):e10940. PubMed ID: 29851833
[TBL] [Abstract][Full Text] [Related]
18. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
19. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
20. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
